Brainomix, an Oxford, UK-based company providing AI-powered imaging tools in stroke and lung fibrosis, raised £14M in Series C funding.
The round was led by co-led by Parkwalk Advisors, and the Boehringer Ingelheim Venture Fund (BIVF), along with new investor Hostplus via the IP Group Hostplus Innovation Fund.
The company intends to use the funds to accelerate its commercial expansion into the US, where it has recently secured ten FDA clearances.
Led by CEO Dr Michalis Papadakis, Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for enhanced treatment decisions in stroke and lung fibrosis. With origins as a spinout from the University of Oxford, it is now expanding at a commercial-stage with offices in the UK, Ireland and the USA, and operations in more than 20 countries.
The company has an ongoing partnership with Boehringer Ingelheim, the global leader in lung fibrosis treatments, to evaluate the real-world impact of e-Lung to improve the identification and access to treatment for people with progressive lung fibrosis.
FinSMEs
20/03/2025